Zobrazeno 1 - 10
of 88
pro vyhledávání: '"Ashkan Mortezavi"'
Autor:
Fredrik Jäderling, Martin Bergman, Jan Chandra Engel, Ashkan Mortezavi, Wolfgang Picker, Erik Skaaheim Haug, Martin Eklund, Tobias Nordström
Publikováno v:
BMC Urology, Vol 24, Iss 1, Pp 1-7 (2024)
Abstract Background Magnetic resonance imaging (MRI) followed by targeted biopsy (TBx) is utilized for prostate cancer (PCa) detection. However, the value of adding systematic biopsies (SBx) to targeted biopsy procedures (combined biopsy; CBx) in men
Externí odkaz:
https://doaj.org/article/98e86aefda1b4e32b1fd063694a1808c
Cost Analysis of Prostate Cancer Care Using a Biomarker-enhanced Diagnostic Strategy with Stockholm3
Autor:
Olga Dianna McLeod, Thorgerdur Palsdottir, Jochen Walz, Derya Tilki, Alberto Briganti, Armando Stabile, Maria Nyre Vigmostad, Ashkan Mortezavi, Anas Elyan, Tim Dudderidge, Tim Govers, Henrik Grönberg, Hari Vigneswaran
Publikováno v:
European Urology Open Science, Vol 66, Iss , Pp 26-32 (2024)
Background and objective: Building on previous research demonstrating better prostate cancer (PC) diagnostics via a biomarker-enhanced approach, this study focuses on cost analysis of PC care using the Stockholm3 test. We assessed the economic impact
Externí odkaz:
https://doaj.org/article/91e0eb096aa34e769833016a33498b48
Autor:
Silvan Sigg, Fabienne Lehner, Etienne Xavier Keller, Karim Saba, Holger Moch, Tullio Sulser, Daniel Eberli, Ashkan Mortezavi
Publikováno v:
BMC Urology, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Introduction Extended pelvic lymph node dissection (ePLND) in men undergoing robot-assisted laparoscopic radical prostatectomy (RARP) is a widely used procedure. However, little is known about anatomical site-specific yields and subsequent m
Externí odkaz:
https://doaj.org/article/739e11d3bfba408ea2ea7695a1baf8cc
Autor:
Christoph Würnschimmel, Dominik Menges, Maciej Kwiatkowski, Silvan Sigg, Lukas Prause, Agostino Mattei, Daniel Engeler, Daniel Eberli, Helge Seifert, Massimo Valerio, Cyrill A. Rentsch, Ashkan Mortezavi
Publikováno v:
Swiss Medical Weekly, Vol 154, Iss 5 (2024)
Over a decade ago, the United States Preventive Services Taskforce (USPSTF) recommended against prostate-specific antigen (PSA)-based screening for prostate cancer in all men, which considerably influenced prostate cancer screening policies worldwide
Externí odkaz:
https://doaj.org/article/5f843392790c4c25b94d4ba6b70e8bf2
Autor:
Thomas P. Scherer, Karim Saba, Marian S. Wettstein, Ilaria Lucca, Ashkan Mortezavi, Sharon Waisbrod, Drahomir Aujesky, Regula Capaul, Raeto T. Strebel
Publikováno v:
Swiss Medical Weekly, Vol 153, Iss 9 (2023)
PURPOSE: Prostate-specific antigen (PSA) screening for men at risk of prostate cancer is controversial. The current recommendation is to raise awareness of prostate cancer and offer PSA screening in accordance with shared decision- making. Whether th
Externí odkaz:
https://doaj.org/article/d0aff695887b41eaa5712fde1dc8916d
Autor:
Daniela A. Ferraro, Andreas M. Hötker, Anton S. Becker, Iliana Mebert, Riccardo Laudicella, Anka Baltensperger, Niels J. Rupp, Jan H. Rueschoff, Julian Müller, Ashkan Mortezavi, Marcelo T. Sapienza, Daniel Eberli, Olivio F. Donati, Irene A. Burger
Publikováno v:
European Journal of Hybrid Imaging, Vol 6, Iss 1, Pp 1-15 (2022)
Abstract Background Magnetic resonance imaging (MRI) is recommended by the European Urology Association guidelines as the standard modality for imaging-guided biopsy. Recently positron emission tomography with prostate-specific membrane antigen (PSMA
Externí odkaz:
https://doaj.org/article/dcbc85ce5c564f4690ca9b48418c5633
Autor:
Jan Chandra Engel, Thorgerdur Palsdottir, Donna Ankerst, Sebastiaan Remmers, Ashkan Mortezavi, Venkatesh Chellappa, Lars Egevad, Henrik Grönberg, Martin Eklund, Tobias Nordström
Publikováno v:
European Urology Open Science, Vol 41, Iss , Pp 1-7 (2022)
Background: External validation of risk calculators (RCs) is necessary to determine their clinical applicability beyond the setting in which these were developed. Objective: To assess the performance of the Rotterdam Prostate Cancer RC (RPCRC) and th
Externí odkaz:
https://doaj.org/article/7c515b49e9124ef4af954a865ea81aa7
Autor:
Bram De Laere, Alessio Crippa, Ashkan Mortezavi, Christophe Ghysel, Prabhakar Rajan, Martin Eklund, Alexander Wyatt, Luc Dirix, Piet Ost, Henrik Grönberg, Johan Lindberg, on behalf of the CORE and ProBio Investigators
Publikováno v:
Cancers, Vol 13, Iss 7, p 1588 (2021)
Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease, characterized by common and rare driver gene alterations that provide a selective growth advantage for progressing tumour cells. We hypothesized that the number of di
Externí odkaz:
https://doaj.org/article/438e2795984f4b44b047adae0de307eb
Autor:
Lotta von Boehmer, Lukas Keller, Ashkan Mortezavi, Maurizio Provenzano, Giovanni Sais, Thomas Hermanns, Tullio Sulser, Achim A Jungbluth, Lloyd J Old, Glen Kristiansen, Maries van den Broek, Holger Moch, Alexander Knuth, Peter J Wild
Publikováno v:
PLoS ONE, Vol 6, Iss 7, p e21366 (2011)
The cancer-testis (CT) family of antigens is expressed in a variety of malignant neoplasms. In most cases, no CT antigen is found in normal tissues, except in testis, making them ideal targets for cancer immunotherapy. A comprehensive analysis of CT
Externí odkaz:
https://doaj.org/article/d8a8d99107fb4759805f824c606c3690
Autor:
Bram, De Laere, Alessio, Crippa, Andrea, Discacciati, Berit, Larsson, Jan, Oldenburg, Ashkan, Mortezavi, Piet, Ost, Martin, Eklund, Johan, Lindberg, Henrik, Grönberg
Publikováno v:
European Urology Focus. 8:1617-1621
ProBio is an outcome-adaptive, multiarm, multiple-assignment randomised, biomarker-driven platform trial in men with metastatic castration-resistant prostate cancer. Here we describe the amended clinical protocol, focusing on expansion of the trial t